Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling
Gang Chen, … , Cagla Eroglu, Ru-Rong Ji
Gang Chen, … , Cagla Eroglu, Ru-Rong Ji
Published October 18, 2022
Citation Information: JCI Insight. 2022;7(23):e161028. https://doi.org/10.1172/jci.insight.161028.
View: Text | PDF
Research Article Neuroscience

Hevin/Sparcl1 drives pathological pain through spinal cord astrocyte and NMDA receptor signaling

  • Text
  • PDF
Abstract

High endothelial venule protein/SPARC-like 1 (hevin/Sparcl1) is an astrocyte-secreted protein that regulates synapse formation in the brain. Here we show that astrocytic hevin signaling plays a critical role in maintaining chronic pain. Compared with WT mice, hevin-null mice exhibited normal mechanical and heat sensitivity but reduced inflammatory pain. Interestingly, hevin-null mice have faster recovery than WT mice from neuropathic pain after nerve injury. Intrathecal injection of WT hevin was sufficient to induce persistent mechanical allodynia in naive mice. In hevin-null mice with nerve injury, adeno-associated-virus–mediated (AAV-mediated) re-expression of hevin in glial fibrillary acidic protein–expressing (GFAP-expressing) spinal cord astrocytes could reinstate neuropathic pain. Mechanistically, hevin is crucial for spinal cord NMDA receptor (NMDAR) signaling. Hevin-potentiated N-Methyl-D-aspartic acid (NMDA) currents are mediated by GluN2B-containing NMDARs. Furthermore, intrathecal injection of a neutralizing Ab against hevin alleviated acute and persistent inflammatory pain, postoperative pain, and neuropathic pain. Secreted hevin that was detected in mouse cerebrospinal fluid (CSF) and nerve injury significantly increased CSF hevin abundance. Finally, neurosurgery caused rapid and substantial increases in SPARCL1/HEVIN levels in human CSF. Collectively, our findings support a critical role of hevin and astrocytes in the maintenance of chronic pain. Neutralizing of secreted hevin with monoclonal Ab may provide a new therapeutic strategy for treating acute and chronic pain and NMDAR-medicated neurodegeneration.

Authors

Gang Chen, Jing Xu, Hao Luo, Xin Luo, Sandeep K. Singh, Juan J. Ramirez, Michael L. James, Joseph P. Mathew, Miles Berger, Cagla Eroglu, Ru-Rong Ji

×

Figure 4

Expression of hevin in spinal astrocytes by intraspinal hevin-AAV reinstates neuropathic pain in hevin-KO mice.

Options: View larger image (or click on image) Download as PowerPoint
Expression of hevin in spinal astrocytes by intraspinal hevin-AAV reinst...
(A) Double immunostaining of hevin (green) and GFAP (red) in SDH. Note hevin is primarily colocalized with GFAP. Scale bars: 100 μm (left); 20 μm (right). The box is enlarged in the right panels. (B) Absence of hevin immunostaining in SDH in hevin-KO mice. Scale bar: 100 μm. (C) Paradigm for measuring mechanical allodynia in hevin-KO mice with intraspinal microinjection of hevin-AAV and hevinΔDE-AAV, given 6 days before CCI. (D) SDH microinjection of AAV-induced reduction in PWT in naive hevin-KO mice. After CCI, mechanical allodynia was significantly more prolonged in hevin-AAV–treated mice than hevinΔDE-AAV–treated mice. n = 6 mice/group. *P < 0.05, 2-way ANOVA followed by Bonferroni’s post hoc test. Green and red arrows indicate the time of virus injection and nerve injury, respectively. (E) Paradigm for measuring mechanical allodynia in hevin-KO mice with intraspinal microinjection of hevin-AAV and hevinΔDE-AAV, given 2 days after CCI. (F) SDH microinjection of hevin-AAV, given after nerve injury, significantly enhanced and prolonged mechanical allodynia in hevin-KO mice vs. hevinΔDE-AAV–treated mice. n = 6 mice/group. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA followed by Bonferroni’s post hoc test. Arrows indicate the time of virus injection and nerve injury. (G) Triple immunostaining of Myc (red), hevin (green), and GFAP (blue) in SDH in hevin-KO mice, 24 days after the ipsilateral SDH hevin-AAV injection. Note hevin expression is absent in the contralateral SDH of hevin-KO mice. Scale bar: 100 μm. (H) Enlarged images in the box of F panel G, with additional merged images for Myc/hevin, Myc/GFAP, and hevin/GFAP. Note hevin+ astrocytes also Myc+/GFAP+ in superficial SDH. Scale bar: 20 μm. All data are shown as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts